Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. Nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins.

Nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance:

•   Filtration – as low as 5 nanometers
•   Flow rate – minimal disruption
•   Filter life – up to 12 months

Nephros was founded in 1997, by healthcare professionals affiliated with Columbia University Medical Center, initially to address the needs of chronic renal failure patients.

The company has developed an alternative to current hemodialysis therapy known as Mid-dilution hemodiafiltration (mid-HDF). Nephros’ proprietary blood purification technologies enable mid-HDF to be offered to chronic renal failure patients. Nephros mid-dilution filters remove a range of harmful substances, specifically substances known as middle molecules, which have been linked to conditions such as carpal tunnel syndrome, dialysis related amyloidosis, and degenerative bone disease in chronic renal failure patients.

Nephros has extended its filtration technologies to meet the demand for liquid purification in other areas, in particular water purification.  Nephros is currently developing its filter technology in individual water purifiers for military applications.

Nephros has over 100 patents issued worldwide based on 15 different inventions which are primarily geared around our expertise as a filter development company, specializing in hollow fiber ultrafiltration membrane technology.